DEA Temporarily Bans Two Potent Synthetic Nitazenes in Schedule I
Published Date: 8/15/2025
Rule
Summary
The DEA is temporarily putting two dangerous drugs, N-pyrrolidino metonitazene and N-pyrrolidino protonitazene, into Schedule I to keep everyone safe. This means strict rules and serious penalties now apply to anyone making, selling, or using these drugs. The change kicks in right away to stop harm before it happens.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Schedule I controls and penalties applied
The DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I. That means the strict regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I substances now apply to anyone who manufactures, distributes, imports, exports, conducts research or instructional activities, performs chemical analysis, reverse distributes, or possesses these drugs.
Immediate action to protect public safety
The DEA says placing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I is necessary "to avoid imminent hazard to public safety," and the temporary scheduling is effective immediately. This action is intended to prevent harms from these two benzimidazole-opioids while the scheduling is in effect.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-15565 — Interim Enforcement Policy for Enforcement Discretion for General Licensee Adoption of Certificate of Compliance Holder-Generated Changes
The NRC is giving general license holders a break by not punishing certain rule slip-ups when they adopt changes made by the Certificate of Compliance holder. This temporary policy helps licensees adjust without stress while keeping safety in check. It affects anyone using these licenses and could save time and money during this transition period.
Next: 2025-15609 — Endangered and Threatened Species; Designation of Critical Habitat for Five Species of Threatened Indo-Pacific Corals; Correction
The National Marine Fisheries Service fixed a small mistake in their July 2025 rule about protecting five threatened Indo-Pacific coral species. They corrected the section numbers that point to important habitat areas, making sure everything matches up perfectly. This update helps keep coral protection clear and on track, with no extra costs or delays.